
Opinion|Videos|May 14, 2024
Treatment Options for mHSPC
In this segment, Dr. Shore will offer an overview of current treatment options for metastatic hormone-sensitive prostate cancer (mHSPC), as outlined in the NCCN Guidelines for Prostate Cancer. He will discuss patient factors that guide the selection of therapeutic agents or combination therapies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Lung Cancer News Roundup: June 2026
2
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
3
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































